AZD-3514 | CAS#1240299-33-5 | androgen receptor inhibitor

MedKoo Cat#: 204540 | Name: AZD-3514

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer.

Chemical Structure

AZD-3514

CAS#1240299-33-5 (free base)

Theoretical Analysis

MedKoo Cat#: 204540

Name: AZD-3514

CAS#: 1240299-33-5 (free base)

Chemical Formula: C25H32F3N7O2

Exact Mass: 519.2570

Molecular Weight: 519.56

Elemental Analysis: C, 57.79; H, 6.21; F, 10.97; N, 18.87; O, 6.16

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1240299-36-8 (maleate) 1240299-33-5 (free base)

Synonym

AZD3514; AZD 3514; AZD-3514.

IUPAC/Chemical Name

1-(4-(2-(4-(1-(3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-1-yl)ethanone

InChi Key

JMEYDSHPKCSIJC-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H32F3N7O2/c1-18(36)33-14-12-32(13-15-33)16-17-37-21-4-2-19(3-5-21)20-8-10-34(11-9-20)23-7-6-22-29-30-24(25(26,27)28)35(22)31-23/h2-5,20H,6-17H2,1H3

SMILES Code

CC(N1CCN(CCOC2=CC=C(C3CCN(C4=NN5C(CC4)=NN=C5C(F)(F)F)CC3)C=C2)CC1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

AZD3514 is currently in Phase I trail. This trial is looking at a new drug called AZD3514 for men who have prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. Doctors often use hormone therapy to treat prostate cancer. This may keep it under control for long periods of time. But researchers are looking for treatments that will help men who have prostate cancer that stops responding to hormone therapy. Prostate cancer needs the hormone testosterone to grow. The testosterone locks into receptors on the cancer cells. AZD3514 works by breaking down these receptors so that testosterone canÂ’t tell the prostate cancer cells to grow.

Product Data

Product Data

Instruction

View handling instruction

Biological target:

AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 μM and has ability of reducing AR protein expression.

In vitro activity:

AZD3514 and AR antagonist Enzalutamide inhibited DHT driven proliferation of LNCaP cells in a dose-dependent manner (Fig.2A-B). The DHT driven proliferation of LAPC4 cells was also inhibited by 10 μM of AZD3514 (Fig. 2C). AZD3514 inhibited the ligand-driven expression of known AR regulated genes PSA and TMPRSS2 in both LNCaP and LAPC4 cells (Fig. 2D-G). In LNCaP cells inhibition of PSA and TMPRSS2 expression by AZD3514 was shown under a range of DHT conditions (0-10 nM) (Fig. 2D and E). AZD3514 was less potent with increasing DHT concentrations, although near complete inhibition of PSA and TMPRSS2 was observed with 10 μM AZD3514 at all concentrations. Importantly, the basal expression of PSA, and TMPRSS2 in LNCaP cells, and PSA in LAPC4s cells, observed in the absence of DHT was also reduced by treatment with AZD3514 (Fig. 2D-G; data re-plotted in Sup. Fig. 1A-D to provide greater clarity). In LNCaP cells AZD3514 inhibited ligand driven PSA and TMPRSS2 expression within 2-4 hours of treatment (Sup. Fig. 1E-G). Reference: Mol Cancer Ther. 2013 Sep; 12(9): 1715–1727. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769207/

In vivo activity:

Comparably to lead compound 1,14 compounds 6b, 10 and 12 (AZD-3514) dosed orally at 50–100 mg/kg twice daily in the Hershberger model for 7 days caused a significant inhibition of testosterone-induced growth of rat seminal vesicles (data not shown), the magnitude of effect being comparable to that seen with bicalutamide dosed at 2 mg/kg. Analysis of plasma samples 18 h subsequent to administration of the final dose showed free concentrations comparable to the IC50 for nuclear AR downregulation. Reference: Bioorg Med Chem Lett. 2013 Apr 1;23(7):1945-8. https://pubmed.ncbi.nlm.nih.gov/23466225/

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	192.47
	Ethanol	100.0	192.47

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 519.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Dunkley TP, Brave SR, Broadbent N, Stratton NC, Trueman D, Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, Jones RD, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN. AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27. doi: 10.1158/1535-7163.MCT-12-1174. Epub 2013 Jul 16. PMID: 23861347; PMCID: PMC3769207. 2. Bradbury RH, Acton DG, Broadbent NL, Brooks AN, Carr GR, Hatter G, Hayter BR, Hill KJ, Howe NJ, Jones RD, Jude D, Lamont SG, Loddick SA, McFarland HL, Parveen Z, Rabow AA, Sharma-Singh G, Stratton NC, Thomason AG, Trueman D, Walker GE, Wells SL, Wilson J, Wood JM. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett. 2013 Apr 1;23(7):1945-8. doi: 10.1016/j.bmcl.2013.02.056. Epub 2013 Feb 21. PMID: 23466225.

In vitro protocol:

In vivo protocol:

1: Bradbury RH, Acton DG, Broadbent NL, Brooks AN, Carr GR, Hatter G, Hayter BR, Hill KJ, Howe NJ, Jones RD, Jude D, Lamont SG, Loddick SA, McFarland HL, Parveen Z, Rabow AA, Sharma-Singh G, Stratton NC, Thomason AG, Trueman D, Walker GE, Wells SL, Wilson J, Wood JM. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett. 2013 Apr 1;23(7):1945-8. doi: 10.1016/j.bmcl.2013.02.056. Epub 2013 Feb 21. PubMed PMID: 23466225.